Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06371638
Status:
COMPLETED
Last Update Posted:
2024-04-19
First Post:
2024-04-14
Brief Title:
Dexmedetomidine and Postoperative Cognitive Dysfunction POCD
Sponsor:
Udayana University
Organization:
Udayana University
Study Overview
Official Title:
Continuous Dexmedetomidine Infusion Reduces Postoperative Cognitive Dysfunction and Postoperative Pain in Patients Undergoing Laparatomy
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CODE-POCD
Brief Summary:
Postoperative cognitive dysfunction POCD affects all age groups and can lead to increased morbidity and more extended hospital stays Dexmedetomidine reduces POCD by inhibiting the increase in proinflammatory cytokines IL-6 and TNF-α and its anti-inflammatory activity contributes to its protective effect Previous studies found that dexmedetomidine reduced POCD incidence in non-cardiac and cardiac surgery Therefore the goal of this study was to specifically investigate if using TCI dexmedetomidine to maintain anaesthesia in laparotomy surgeries reduces the incidence of POCD compared to inhalation anaesthesia by sevoflurane
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None